<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pyridostigmine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pyridostigmine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pyridostigmine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11416" href="/d/html/11416.html" rel="external">see "Pyridostigmine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12752" href="/d/html/12752.html" rel="external">see "Pyridostigmine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F215907"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Mestinon;</li>
<li>Regonol</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868081"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>JAMP-Pyridostigmine Bromide;</li>
<li>Mestinon;</li>
<li>Mestinon SR;</li>
<li>RIVA-Pyridostigmine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F215948"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Acetylcholinesterase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F215911"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c0a8a050-cc71-45aa-bc5d-3cac3c9c461a">Myasthenia gravis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myasthenia gravis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Recommendations provided are general guidelines only; dosing should be highly individualized, taking into account symptom severity and tolerance of side effects.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release</i>: <b>Oral:</b> Initial: 30 to 60 mg 3 times daily; may increase in increments of 30 mg/dose every 2 to 3 days based on response and tolerability to 60 to 120 mg every 3 to 4 hours while awake (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bird.1','lexi-content-ref-29655452']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bird.1','lexi-content-ref-29655452'])">Ref</a></span>). Usual total daily dose: ≤960 mg/day divided into 4 to 8 doses (each dose administered no sooner than every 3 hours while awake); total daily doses higher than 450 to 600 mg/day may be associated with increased side effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bird.1','lexi-content-ref-21815707']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bird.1','lexi-content-ref-21815707'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Sustained release (alternative formulation): </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> It may be necessary to use IR therapy in conjunction with sustained-release therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>180 to 360 mg once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21815707','lexi-content-ref-20663605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21815707','lexi-content-ref-20663605'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>IM, IV (off-label): </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>For use when oral therapy is impractical. IM route preferred due to significant complications (eg, cardiac arrest) observed with IV route (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21815707','lexi-content-ref-23563874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21815707','lexi-content-ref-23563874'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM, IV:</b> One-thirtieth of oral dose; may repeat every 3 to 4 hours (example: patient’s maintenance oral dose is 60 mg oral pyridostigmine; may administer 2 mg IM/IV) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21815707','lexi-content-ref-23563874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21815707','lexi-content-ref-23563874'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Discontinuation of therapy: </i>Avoid abrupt discontinuation except in the case of severe adverse drug reaction (eg, cholinergic crisis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21815707']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21815707'])">Ref</a></span>). For patients with stable myasthenia gravis (eg, stabilized on chronic immunosuppression), may reduce daily pyridostigmine dose gradually by ~30 mg per week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32733360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32733360'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b2d2bcf-2892-4c38-946f-df5b5abfc5de">Postural orthostatic tachycardia syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postural orthostatic tachycardia syndrome (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 30 mg twice daily; may increase dose at intervals of 1 to 2 weeks to 30 to 60 mg up to 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32145864','lexi-content-ref-21410722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32145864','lexi-content-ref-21410722'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b1d9b6e-fb5c-454e-bf4f-f289910d889f">Reversal of nondepolarizing neuromuscular blocking agents</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of nondepolarizing neuromuscular blocking agents:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Monitor muscle twitch response to peripheral nerve stimulation; administer pyridostigmine after spontaneous recovery of neuromuscular function has begun. Atropine sulfate or glycopyrrolate IV should be administered immediately prior to or simultaneously with pyridostigmine to minimize side effects. Inadequate reversal is possible; manage by manual or mechanical ventilation until recovery is judged adequate (additional doses are not recommended).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 0.1 to 0.25 mg/kg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="01eb2528-d4e3-4af9-9871-1461e21caa43">Disopyramide-induced anticholinergic adverse effects</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Disopyramide-induced anticholinergic adverse effects (off-label use): Oral:</b> Sustained release: 90 to 180 mg every 12 hours or as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23704138','lexi-content-ref-26818487','lexi-content-ref-3624669']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23704138','lexi-content-ref-26818487','lexi-content-ref-3624669'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990478"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, lower initial doses may be required due to prolonged elimination in renal impairment.</p></div>
<div class="block doha drugH1Div" id="F50987753"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F215912"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F215928"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12752" href="/d/html/12752.html" rel="external">see "Pyridostigmine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f8ef4fe-9d3c-4d60-8af2-99b0d1bc0d8b">Myasthenic syndromes, congenital</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myasthenic syndromes, congenital:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Therapeutic response dependent upon inherited genetic variation and resultant type of myasthenic syndrome; pyridostigmine use should be under the supervision of a specialist experienced in the diagnosis and management of congenital myasthenic syndromes; some syndromes may be worsened by pyridostigmine therapy (eg, slow-channel myasthenic syndrome) and pyridostigmine use should be avoided (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31794470','lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31794470','lexi-content-ref-Kliegman.1'])">Ref</a></span>). Dosage should be individualized based on patient response.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: Immediate release: 1 mg/kg/dose every 4 hours; usual range: 4 to 5 mg/kg/day in 4 to 6 divided doses; maximum daily dose: 7 mg/kg/<b>day</b> divided in 5 to 6 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1','lexi-content-ref-22353287']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1','lexi-content-ref-22353287'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="04bf080b-f585-4588-9402-898bd2ecfa12">Myasthenia gravis, autoimmune</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myasthenia gravis, autoimmune (juvenile):</b> Limited data available: <b>Note:</b> Pyridostigmine usually considered part of initial treatment for most patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27358333']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27358333'])">Ref</a></span>). Dosage should be adjusted such that larger doses administered prior to time of greatest fatigue.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Immediate release: 0.5 to 1 mg/kg/dose every 4 to 6 hours; usual maximum single dose: 60 mg/dose; maximum daily dose: 7 mg/kg/<b>day</b> in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1'])">Ref</a></span>); in adults, therapeutic effects usually observed at total daily doses &lt;960 mg/day divided into 4 to 8 doses; in some pediatric patients, doses as high as 1,500 mg/<b>day</b> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9668332','lexi-content-ref-Kliegman.1','lexi-content-ref-21815707']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9668332','lexi-content-ref-Kliegman.1','lexi-content-ref-21815707'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IM, IV: 0.05 to 0.15 mg/kg/dose; maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="21383704-4e49-42e1-b6cc-3648e1f88534">Reversal of nondepolarizing neuromuscular blocker</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of nondepolarizing neuromuscular blocker:</b> Limited data available: <b>Note:</b> Pyridostigmine rarely used; other agents (eg, neostigmine, sugammadex) have routine place in therapy. Administer atropine or glycopyrrolate immediately prior to minimize side effects.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IM, IV: 0.1 to 0.25 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c1372834-168b-4d82-a7ad-7f4fc8466156">Vincristine-induced neurotoxicity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vincristine-induced neurotoxicity:</b> Very limited data available; efficacy results variable: Children ≥2 years and Adolescents: Oral: Immediate release: 3 mg/kg/day divided in 2 doses, in combination with pyridoxine for 3 weeks; dosing based on a case series of 4 children (age: 2 to 13 years) receiving vincristine for treatment of acute lymphoblastic leukemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20532679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20532679'])">Ref</a></span>) and a 2-year-old receiving vincristine for a cervical synovial sarcoma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14752870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14752870'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51159533"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments are provided in the manufacturer's labeling; however, lower doses may be required due to prolonged elimination; dosage titration should be based on drug effects.</p></div>
<div class="block dohp drugH1Div" id="F51159534"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments are provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F58688448"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiac effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase inhibitors, including pyridostigmine, have been associated with cardiac effects, including <b>bradycardia</b>, <b>atrioventricular block</b>, and <b>syncope</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3812546','lexi-content-ref-4005684','lexi-content-ref-30357043','lexi-content-ref-4355635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3812546','lexi-content-ref-4005684','lexi-content-ref-30357043','lexi-content-ref-4355635'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Related to the mechanism of action; increased cholinergic stimulation of the parasympathetic nervous system results in reduced automaticity of the sinus node leading to bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; bradycardia occurred within 4 minutes of IV administration (administered in combination with atropine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4355635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4355635'])">Ref</a></span>) and within 120 minutes of oral administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9196546']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9196546'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Administration without concomitant anticholinergic agent (eg, atropine, glycopyrrolate) for neuromuscular blockade reversal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7258611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7258611'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with preexisting conduction defects without a functioning pacemaker (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3812546','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3812546','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant risk factors for bradyarrhythmias (eg, electrolyte abnormalities, infection, hypothyroidism) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of cardiac glycosides (eg, digoxin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-565156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-565156'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32733360','lexi-content-ref-565156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32733360','lexi-content-ref-565156'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Gastrointestinal effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal effects including <b>abdominal cramps</b>, <b>diarrhea</b>, <b>increased peristalsis</b>, <b>nausea</b>, <b>sialorrhea</b>, and <b>vomiting</b> have been reported with pyridostigmine and may lead to dose reduction or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21410722','lexi-content-ref-36184373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21410722','lexi-content-ref-36184373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Related to the mechanism of action; increased cholinergic activity increases smooth muscle contraction, peristalsis, and sphincter relaxation in the GI tract (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21815707']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21815707'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; in one study, abdominal discomfort and sialorrhea were reported within 120 minutes of oral administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9196546']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9196546'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Doses &gt;450 to 600 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21815707']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21815707'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dose titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32733360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32733360'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18069667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18069667'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of dysphagia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32733360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32733360'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Respiratory effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Respiratory effects, including <b>increased bronchial secretions</b> and <b>bronchoconstriction</b>, have been reported with pyridostigmine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3970800','lexi-content-ref-21815707']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3970800','lexi-content-ref-21815707'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Related to the mechanism of action; increased cholinergic activity increases bronchial smooth muscle constriction and bronchial secretions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1757243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1757243'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; a reduction in FEV<sub>1</sub> (-1.6% from baseline) occurred within 14 minutes of IV administration (administered in combination with atropine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3970800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3970800'])">Ref</a></span>); a reduction in FVC (-4.3% of predicted from baseline) occurred within 2 hours following oral administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32207521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32207521'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of asthma or obstructive lung disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32733360','lexi-content-ref-32207521','lexi-content-ref-1757243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32733360','lexi-content-ref-32207521','lexi-content-ref-1757243'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F215873"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Increased peristalsis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Fasciculations</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Miosis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrioventricular block (Chaucer 2018), bradycardia (Fogdall 1973), syncope (Arsura 1987), thrombophlebitis (IV)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (Maggi 2011), skin rash (Maggi 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps (Remijn-Nelissen 2022), bloating (Kanjwal 2011), diarrhea (Remijn-Nelissen 2022), flatulence (Remijn-Nelissen 2022), nausea (Kanjwal 2011), sialorrhea (Maggi 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary urgency (Remijn-Nelissen 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (Castellano 1998)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Tingling of extremities (fingers and toes) (Maggi 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps (Remijn-Nelissen 2022), muscle twitching (Remijn-Nelissen 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchoconstriction (Feldt-Rasmussen 1985), increased bronchial secretions (Maggi 2011)</p></div>
<div class="block coi drugH1Div" id="F215888"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to pyridostigmine, anticholinesterase agents, or any component of the formulation; mechanical intestinal or urinary obstruction</p></div>
<div class="block war drugH1Div" id="F215871"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cholinergic effects: Symptoms of excess cholinergic activity may occur (eg, salivation, sweating, urinary incontinence). Overdosage may result in cholinergic crisis (eg, muscle weakness), which must be distinguished from myasthenic crisis; discontinue immediately in the presence of cholinergic crisis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: May occur; have atropine and epinephrine ready to treat hypersensitivity reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution; additive effect with antiglaucoma drugs may cause or exacerbate problems with night vision.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; initial lower doses may be needed; titrate to effect.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bromide sensitivity: Use with caution in patients with bromide sensitivity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Must be administered by trained personnel; use of peripheral nerve stimulation to monitor neuromuscular function recovery and continuous patient observation until recovery of normal respiration is recommended. To counteract anticholinergic effects, use of glycopyrrolate or atropine sulfate simultaneously with or prior to administration is recommended. May contain benzyl alcohol which has been associated with "gasping syndrome" in neonates.</p>
<p style="text-indent:-2em;margin-left:4em;">• Oral: Adequate facilities should be available for cardiopulmonary resuscitation when testing and adjusting dose for myasthenia gravis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Inadequate reversal of nondepolarizing neuromuscular blocking agents: Inadequate reversal induced by nondepolarizing neuromuscular blocking agents is possible; manage with manual or mechanical ventilation until recovery is adequate (additional doses not recommended). Failure to produce prompt (within 30 minutes) reversal of neuromuscular blockade may occur in the presence of extreme debilitation, carcinomatosis, or with concomitant use of certain broad-spectrum antibiotics, or anesthetic agents and other drugs which enhance neuromuscular blockade or cause respiratory depression.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878616"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Neonates of myasthenic mothers may have transient difficulties in swallowing, sucking, and breathing; use of pyridostigmine may be of benefit; use edrophonium test to assess neonate with these symptoms. </p></div>
<div class="block foc drugH1Div" id="F215882"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as bromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Regonol: 10 mg/2 mL (2 mL) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as bromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mestinon: 60 mg/5 mL (473 mL) [contains alcohol, usp, fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), sodium benzoate; raspberry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 60 mg/5 mL (5 mL, 473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as bromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mestinon: 60 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg, 60 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral, as bromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mestinon: 180 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 180 mg</p></div>
<div class="block geq drugH1Div" id="F215867"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F215890"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Mestinon Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg/5 mL (per mL): $4.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (pyRIDostigmine Bromide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg/5 mL (per mL): $2.83 - $3.24</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Regonol Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/2 mL (per mL): $16.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Mestinon Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $45.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (pyRIDostigmine Bromide ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $24.81 - $24.83</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Mestinon Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $24.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (pyRIDostigmine Bromide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $8.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $0.15 - $1.61</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868082"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as bromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mestinon: 60 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 60 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral, as bromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mestinon SR: 180 mg</p></div>
<div class="block adm drugH1Div" id="F215885"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Do <b>not</b> crush ER tablet.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. ER tablets should be swallowed whole. Do not break, crush, or chew. IR tablet, oral solution, syrup, and injectable formulations are available.</p>
<p style="text-indent:-2em;margin-left:6em;">If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, selection of IR pyridostigmine formulations should be strongly considered in those with severe myasthenia gravis symptoms or when using for nerve gas exposure prophylaxis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer as slow IV push (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8504663']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8504663'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613749"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Oral: Swallow sustained release tablets whole, do not chew or crush </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Parenteral: May administer IM or as a direct IV slowly over 2-4 minutes; patients receiving large parenteral doses should be pretreated with atropine </p></div>
<div class="block use drugH1Div" id="F215884"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Myasthenia gravis (oral only):</b> Treatment of symptoms associated with myasthenia gravis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of nondepolarizing neuromuscular blocking agents (injection only):</b> Reversal agent or antagonist of nondepolarizing neuromuscular blocking agents.</p></div>
<div class="block off-label drugH1Div" id="F27261185"><span class="drugH1">Use: Off-Label: Adult</span><p>Disopyramide-induced anticholinergic adverse effects; Postural orthostatic tachycardia syndrome</p></div>
<div class="block mst drugH1Div" id="F215957"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">PyRIDostigmine may be confused with PHYSostigmine, pyridoxine</p>
<p style="text-indent:-2em;margin-left:4em;">Regonol may be confused with Reglan, Renagel</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299967"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F215875"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Amifampridine. Amifampridine side effects may also be increased. Amifampridine may enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase inhibitor side effects may also be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: Acetylcholinesterase Inhibitors may diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benoxinate: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Chlorprothixene. Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists. Specifically, cholinergic effects may be enhanced or increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kanamycin: PyRIDostigmine may diminish the therapeutic effect of Kanamycin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Acetylcholinesterase Inhibitors may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F215891"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Pyridostigmine may cross the placenta (Buckley 1968).</p>
<p style="text-indent:0em;margin-top:2em;">Oral pyridostigmine is the agent of choice for treating myasthenia gravis during pregnancy; the IV route may cause uterine contractions and is not recommended (Sanders 2016). Use should be continued during labor (Norwood 2014). Transient neonatal myasthenia gravis may occur in neonates due to placental transfer of maternal antibodies (Norwood 2014; Sanders 2016).</p>
<p style="text-indent:0em;margin-top:2em;">In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>
<div class="block brc drugH1Div" id="F215892"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Pyridostigmine is present in breast milk (Hardell 1982).</p>
<p style="text-indent:-2em;margin-left:2em;">Information is available from two mothers using pyridostigmine for myasthenia gravis throughout pregnancy and postpartum. Maternal doses ranged from 120 mg to 300 mg/day and sampling occurred from 5 to 102 days after delivery. Milk concentrations averaged ≤0.1% of the weight-adjusted maternal dose (n=2); infant plasma concentrations were less than the limit of quantification (&lt;2 ng/mL; n=1) (Hardell 1982).</p>
<p style="text-indent:-2em;margin-left:2em;">Disease exacerbations may occur in breastfeeding women with poorly controlled myasthenia gravis due to fatigue associated with breastfeeding. Babies born to women with myasthenia gravis may have feeding difficulties due to transient myasthenia gravis of the newborn (Norwood 2014). Breastfed infants should be monitored for fatigue associated with transient neonatal myasthenia gravis (Varner 2013); however, current guidelines note that breastfeeding is acceptable in women taking pyridostigmine for myasthenia gravis (Norwood 2014).</p></div>
<div class="block mop drugH1Div" id="F215880"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">ECG, blood pressure, and heart rate especially when administered IV; cholinergic reactions (eg, nausea, vomiting, diarrhea, increased salivation) especially when administered IV; consult individual institutional policies and procedures.</p></div>
<div class="block pha drugH1Div" id="F215870"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits destruction of acetylcholine by acetylcholinesterase which facilitates transmission of impulses across neuromuscular junction</p></div>
<div class="block phk drugH1Div" id="F215887"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Recovery from vincristine neurotoxicity: Onset of action: 1 to 2 weeks (Akbayram 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">Myasthenia gravis: Oral: Within 30 minutes (Maggi 2011); IM: 15 to 30 minutes; IV: Within 2 to 5 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Reversal of nondepolarizing neuromuscular blocking agents: IV: Return of twitch height to 90% of control occurs within ~6 minutes following administration of 0.25 mg/kg dose; at lower doses, full recovery usually occurs within 15 to 30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Oral: 3 to 4 hours in the daytime (Maggi 2011); IM, IV: 2 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Very poor.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.53 to 1.76 L/kg (Aquilonius 1986).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: None (Aquilonius 1986).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic and at tissue site by cholinesterases.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 10% to 20% (Aquilonius 1986).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 1 to 2 hours; renal failure: ~6 hours (Aquilonius 1986).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: ~1.5 hours (Aquilonius 1980).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Oral: 1 to 2 hours (Aquilonius 1986).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (80% to 90% as unchanged drug) (Aquilonius 1986).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F215893"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Mestinon timespan</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Mestinon | Piridostigmina</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Lodmin | Mestinon | Piridostigmina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Kalymin N | Mestinon | Mestinon retard</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Piridostigmina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Mestinon | Pystinon | Stigmide</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Mestinon | Pyridostigmine</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Pyridostigmine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Gravitor | Mestinon | Mustone | Myestin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Brimine | Dosmin | Mestinon | Metine | Pyrinol</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Distinon | Flagmine | Mestinon</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Brigadan t | Mestinon | Mestinon timespan | Monaxyl | Piridostigmina | Tumata</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Mestinon | Pyrimine | Pyrinol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Mestinon | Mestinon 10</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Amygra | Mestinon | Pyrostig</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Brostagin | Mestinon</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Mestinon | Pyridostigmine br | Pyridostigmine bromide extended release | Regonol</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Mestinon | Piridostigmina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Kalymin 60 n</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Antilon | Mestinon</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Kalymin | Mestinon</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Mestinon | Mestinon ts</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Diluxen | Mestinon</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Mestinon</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319. doi:10.1067/mpd.2001.116281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20532679">
<a name="20532679"></a>Akbayram S, Akgun C, Doğan M, Sayin R, Caksen H, Oner AF. Use of pyridoxine and pyridostigmine in children with vincristine-induced neuropathy. <i>Indian J Pediatr</i>. 2010;77(6):681-683. doi:10.1007/s12098-010-0096-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/20532679/pubmed" id="20532679" target="_blank">20532679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9668332">
<a name="9668332"></a>Andrews PI. A treatment algorithm for autoimmune myasthenia gravis in childhood. <i>Ann N Y Acad Sci</i>. 1998;841:789-802. doi:10.1111/j.1749-6632.1998.tb11020.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/9668332/pubmed" id="9668332" target="_blank">9668332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3524957">
<a name="3524957"></a>Aquilonius SM, Hartvig P. Clinical pharmacokinetics of cholinesterase inhibitors. <i>Clin Pharmacokinet</i>. 1986;11(3):236-249. doi:10.2165/00003088-198611030-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/3524957/pubmed" id="3524957" target="_blank">3524957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7439266">
<a name="7439266"></a>Aquilonius SM, Eckernäs SA, Hartvig P, Lindström B, Osterman PO. Pharmacokinetics and oral bioavailability of pyridostigmine in man. <i>Eur J Clin Pharmacol</i>. 1980;18(5):423-428. doi:10.1007/BF00636797<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/7439266/pubmed" id="7439266" target="_blank">7439266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3812546">
<a name="3812546"></a>Arsura EL, Brunner NG, Namba T, Grob D. Adverse cardiovascular effects of anticholinesterase medications. <i>Am J Med Sci</i>. 1987;293(1):18-23. doi:10.1097/00000441-198701000-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/3812546/pubmed" id="3812546" target="_blank">3812546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140. doi: 10.1002/bdra.10007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4005684">
<a name="4005684"></a>Bates CP. Muscarinic cardiac effects of pyridostigmine. <i>Can Anaesth Soc J</i>. 1985;32(3 Pt 1):315-316. doi:10.1007/BF03015154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/4005684/pubmed" id="4005684" target="_blank">4005684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bird.1">
<a name="Bird.1"></a>Bird SJ. Overview of the treatment of myasthenia gravis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed February 22, 2022. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5692081">
<a name="5692081"></a>Buckley GA, Roberts DV, Roberts JB, Thomas BH, Wilson A. Drug-induced neonatal myasthenia. <i>Br J Pharmacol</i>. 1968;34(1):203P-204P.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/5692081/pubmed" id="5692081" target="_blank">5692081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9860251">
<a name="9860251"></a>Castellano A, Cabrera M, Robledo T, et al. Anaphylaxis by pyridostigmine. <i>Allergy</i>. 1998;53(11):1108-1109. doi:10.1111/j.1398-9995.1998.tb03828.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/9860251/pubmed" id="9860251" target="_blank">9860251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30357043">
<a name="30357043"></a>Chaucer B, Whelan D, Lamichhane D. Pyridostigmine induced heart block requiring ICU admission. <i>J Community Hosp Intern Med Perspect</i>. 2018;8(5):283-284. doi:10.1080/20009666.2018.1527668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/30357043/pubmed" id="30357043" target="_blank">30357043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31794470">
<a name="31794470"></a>Ciafaloni E. Myasthenia gravis and congenital myasthenic syndromes. <i>Continuum (Minneap Minn)</i>. 2019;25(6):1767-1784. doi:10.1212/CON.0000000000000800<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/31794470/pubmed" id="31794470" target="_blank">31794470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29655452">
<a name="29655452"></a>Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of myasthenia gravis. <i>Neurol Clin.</i> 2018;36(2):311-337. doi:10.1016/j.ncl.2018.01.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/29655452/pubmed" id="29655452" target="_blank">29655452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32733360">
<a name="32733360"></a>Farrugia ME, Goodfellow JA. A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature. <i>Front Neurol.</i> 2020;11:604. doi:10.3389/fneur.2020.00604<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/32733360/pubmed" id="32733360" target="_blank">32733360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3970800">
<a name="3970800"></a>Feldt-Rasmussen BF, Gefke K, Mosbech H, Hanel HK. Effect of a mixture of pyridostigmine and atropine on forced expiratory volume (FEV1), and serum cholinesterase activity in normal subjects. <i>Br J Anaesth</i>. 1985;57(2):204-207. doi:10.1093/bja/57.2.204<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/3970800/pubmed" id="3970800" target="_blank">3970800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4355635">
<a name="4355635"></a>Fogdall RP, Miller RD. Antagonism of d-tubocurarine- and pancuronium-induced neuromuscular blockades by pyridostigmine in man. <i>Anesthesiology</i>. 1973;39(5):504-509. doi:10.1097/00000542-197311000-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/4355635/pubmed" id="4355635" target="_blank">4355635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32207521">
<a name="32207521"></a>Hansen MR, Schlünssen V. Pyridostigmine impairs pulmonary function in asthmatic subjects: Reanalysis of results from an observational study. <i>Mil Med</i>. 2020;185(7-8):e934-e936. doi:10.1093/milmed/usaa055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/32207521/pubmed" id="32207521" target="_blank">32207521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7138742">
<a name="7138742"></a>Hardell LI, Lindström B, Lönnerholm G, Osterman PO. Pyridostigmine in human breast milk. <i>Br J Clin Pharmacol</i>. 1982;14(4):565-567.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/7138742/pubmed" id="7138742" target="_blank">7138742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278. doi: 10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21410722">
<a name="21410722"></a>Kanjwal K, Karabin B, Sheikh M, et al. Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience. <i>Pacing Clin Electrophysiol.</i> 2011;34(6):750-755. doi:10.1111/j.1540-8159.2011.03047.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/21410722/pubmed" id="21410722" target="_blank">21410722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7258611">
<a name="7258611"></a>Long G, Marsh HM. The effect on heart rate of neuromuscular blockade reversal by pyridostigmine. <i>Anaesth Intensive Care</i>. 1981;9(2):144-146. doi:10.1177/0310057X8100900208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/7258611/pubmed" id="7258611" target="_blank">7258611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22353287">
<a name="22353287"></a>Lorenzoni PJ, Scola RH, Kay CS, Werneck LC. Congenital myasthenic syndrome: a brief review. <i>Pediatr Neurol</i>. 2012;46(3):141-148. doi:10.1016/j.pediatrneurol.2011.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/22353287/pubmed" id="22353287" target="_blank">22353287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21815707">
<a name="21815707"></a>Maggi L, Mantegazza R. Treatment of myasthenia gravis: focus on pyridostigmine. <i>Clin Drug Investig</i>. 2011;31(10):691-701. doi:10.2165/11593300-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/21815707/pubmed" id="21815707" target="_blank">21815707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mestinon.1">
<a name="Mestinon.1"></a>Mestinon (pyridostigmine) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14752870">
<a name="14752870"></a>Müller L, Kramm CM, Tenenbaum T, Wessalowski R, Göbel U. Treatment of vincristine-induced bilateral ptosis with pyridoxine and pyridostigmine. <i>Pediatr Blood Cancer</i>. 2004;42(3):287-288. doi:10.1002/pbc.10301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/14752870/pubmed" id="14752870" target="_blank">14752870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9196546">
<a name="9196546"></a>Nóbrega AC, Carvalho AC, Bastos BG. Resting and reflex heart rate responses during cholinergic stimulation with pyridostigmine in humans. <i>Braz J Med Biol Res</i>. 1996;29(11):1461-1465.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/9196546/pubmed" id="9196546" target="_blank">9196546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23757420">
<a name="23757420"></a>Norwood F, Dhanjal M, Hill M, et al. Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group. <i>J Neurol Neurosurg Psychiatry</i>. 2014;85(5):538-543. doi:10.1136/jnnp-2013-305572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/23757420/pubmed" id="23757420" target="_blank">23757420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-565156">
<a name="565156"></a>Owens WD, Waldbaum LS, Stephen CR. Cardiac dysrhythmia following reversal of neuromuscular blocking agents in geriatric patients. <i>Anesth Analg</i>. 1978;57(2):186-190.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/565156/pubmed" id="565156" target="_blank">565156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18069667">
<a name="18069667"></a>Punga AR, Sawada M, Stålberg EV. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. <i>Muscle Nerve</i>. 2008;37(3):300-307. doi:10.1002/mus.20935<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/18069667/pubmed" id="18069667" target="_blank">18069667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15911704">
<a name="15911704"></a>Raj SR, Black BK, Biaggioni I, Harris PA, Robertson D. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. <i>Circulation</i>. 2005;111(21):2734-2740. doi:10.1161/CIRCULATIONAHA.104.497594<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/15911704/pubmed" id="15911704" target="_blank">15911704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32145864">
<a name="32145864"></a>Raj SR, Guzman JC, Harvey P, et al. Canadian Cardiovascular Society position statement on postural orthostatic tachycardia syndrome (POTS) and related disorders of chronic orthostatic intolerance. <i>Can J Cardiol.</i> 2020;36(3):357-372. doi:10.1016/j.cjca.2019.12.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/32145864/pubmed" id="32145864" target="_blank">32145864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1757243">
<a name="1757243"></a>Ram Z, Molcho M, Danon YL, Almog S, Baniel J, Karni A, Shemer J. The effect of pyridostigmine on respiratory function in healthy and asthmatic volunteers. <i>Isr J Med Sci</i>. 1991;27(11-12):664-668.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/1757243/pubmed" id="1757243" target="_blank">1757243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Regonol.1">
<a name="Regonol.1"></a>Regonol (pyridostigmine) [prescribing information]. Princeton, NJ: Sandoz Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36184373">
<a name="36184373"></a>Remijn-Nelissen L, Verschuuren JJGM, Tannemaat MR. The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study. <i>Neuromuscul Disord</i>. 2022;32(10):790-799. doi:10.1016/j.nmd.2022.09.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/36184373/pubmed" id="36184373" target="_blank">36184373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8504663">
<a name="8504663"></a>Saltis LM, Martin BR, Traeger SM, Bonfiglio MF. Continuous infusion of pyridostigmine in the management of myasthenic crisis. <i>Crit Care Med</i>. 1993;21(6):938-940.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/8504663/pubmed" id="8504663" target="_blank">8504663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27358333">
<a name="27358333"></a>Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. <i>Neurology</i>. 2016;87(4):419-425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/27358333/pubmed" id="27358333" target="_blank">27358333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25980576">
<a name="25980576"></a>Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. <i>Heart Rhythm</i>. 2015;12(6):e41-e63. doi:10.1016/j.hrthm.2015.03.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/25980576/pubmed" id="25980576" target="_blank">25980576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26818487">
<a name="26818487"></a>Sherrid MV. Drug therapy for hypertrophic cardiomyopathy: physiology and practice. <i>Curr Cardiol Rev</i>. 2016;12(1):52-65. doi:10.2174/1573403x1201160126125403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/26818487/pubmed" id="26818487" target="_blank">26818487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23704138">
<a name="23704138"></a>Sherrid MV, Shetty A, Winson G, et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil. <i>Circ Heart Fail</i>. 2013;6(4):694-702. doi:10.1161/CIRCHEARTFAILURE.112.000122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/23704138/pubmed" id="23704138" target="_blank">23704138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20663605">
<a name="20663605"></a>Sieb JP, Köhler W. Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial.<i> Clin Neurol Neurosurg.</i> 2010;112(9):781-784. doi:10.1016/j.clineuro.2010.06.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/20663605/pubmed" id="20663605" target="_blank">20663605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3624669">
<a name="3624669"></a>Teichman SL, Ferrick A, Kim SG, et al. Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect. <i>J Am Coll Cardiol</i>. 1987;10(3):633-641. doi:10.1016/s0735-1097(87)80207-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/3624669/pubmed" id="3624669" target="_blank">3624669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: A scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23563874">
<a name="23563874"></a>Varner M. Myasthenia gravis and pregnancy. <i>Clin Obstet Gynecol</i>. 2013;56(2):372-381. doi:10.1097/GRF.0b013e31828e92c0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/23563874/pubmed" id="23563874" target="_blank">23563874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26684556">
<a name="26684556"></a>Verlinden NJ, Coons JC. Disopyramide for hypertrophic cardiomyopathy: a pragmatic reappraisal of an old drug. <i>Pharmacotherapy</i>. 2015;35(12):1164-1172. doi:10.1002/phar.1664<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/26684556/pubmed" id="26684556" target="_blank">26684556</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9838 Version 335.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
